What Liprosil 450 Treats: Main Uses and Benefits

Liprosil 450 (Gemfibrozil) is used to manage specific, persistent abnormalities in blood fat profiles that may pose health risks, and is applied as an adjunct when diet and lifestyle measures are insufficient. This medication is commonly used across two primary therapeutic domains.

---

Managing Severe Hypertriglyceridemia and Associated Risk

This medication is commonly used across conditions presenting with very high triglycerides that are associated with a risk of acute pancreatitis. The treatment provides supportive benefit by helping to reduce the overall burden of elevated fat levels, which may assist in lessening the associated health risk. It is relevant in clinical settings marked by increased physiological stress related to lipid levels.

“The therapy supports the patient during difficult episodes by easing distress related to abnormal fat composition.”

---

Correcting Mixed Dyslipidemia and Supporting Cardiovascular Health

Liprosil 450 helps address symptom clusters that may become intense or disruptive in cases of mixed dyslipidemia, characterized by both elevated VLDL and triglycerides, alongside abnormally low levels of HDL cholesterol. This rebalancing supports the management of the long-term cardiovascular risk profile, which contributes to easing the overall symptom load associated with heart disease.

Quick Fact: Relevant for Managing Elevated Triglycerides

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Liprosil 450?

This section defines eligibility for Liprosil 450 (Gemfibrozil) based strictly on official regulatory labeling.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed:	Adult patients for whom diet alone has not been sufficient, specifically those with severe hypertriglyceridaemia or mixed hyperlipidaemia.
Populations for whom use is not recommended:	The pediatric population (children and adolescents) as safety and efficacy have not been established. Use is generally avoided during pregnancy and lactation.

Contraindicated Populations

Liprosil 450 is formally contraindicated in patients with:

• Severe renal impairment or hepatic impairment (liver disorders).
• A history of or pre-existing gallbladder disease or biliary tract disease.
• Known hypersensitivity to Gemfibrozil.
• Concomitant use with certain medications, including Simvastatin, Repaglinide, Dasabuvir, and Selexipag.

Resulting Eligibility Structure

Official regulatory documents define who can and cannot use this medicine primarily by establishing absolute contraindications related to organ function and specific comorbidities. Eligibility is further restricted by age, and special caution is required for conditions like mild renal impairment or uncontrolled metabolic disorders like diabetes, which must be stabilized prior to use.

Interactions with other medicines and products

Liprosil 450 (Gemfibrozil) has formally documented interaction patterns arising primarily from its ability to inhibit specific metabolic enzymes and transport proteins.

Official Contraindications and Prohibited Combinations

Regulatory labeling dictates that co-administration with the following substances is strictly contraindicated:

Interacting Substance	Official Interaction Rationale
Statins (e.g., Simvastatin)	Significantly increased risk of severe muscle toxicity, including rhabdomyolysis.
Repaglinide	Multi-fold increase in plasma concentration, risking severe and prolonged hypoglycemia.
Dasabuvir, Selexipag	Prohibited due to substantially increased exposure of the co-administered agent.

---

Other Clinically Relevant Interactions

Liprosil 450 is a documented inhibitor of the CYP2C8 enzyme and the OATP1B1 transporter, which increases the systemic exposure of co-administered agents metabolized by these pathways. For drugs like Coumarin Anticoagulants (e.g., Warfarin), the potential for pharmacodynamic potentiation requires dosage reduction and mandatory increased INR monitoring. The risk of myopathy is also officially noted as being increased when combined with Colchicine.

Timing-Based Rule: Doses must be administered at least 2 hours apart from Bile Acid Sequestrants (e.g., Colestipol) to prevent reduced absorption. Additionally, official regulatory documents caution that alcohol intake should be limited or avoided due to its potential to interfere with the treatment's efficacy by raising triglyceride levels.

How Liprosil 450 Works

Liprosil 450, whose active compound is Gemfibrozil, exerts its primary action by modulating gene transcription related to lipid processing. The molecule functions as an agonist for the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha), a nuclear receptor highly expressed in the liver and other metabolically active tissues.

Activation of PPARalpha initiates a cascade of programmed changes in cellular enzyme and protein synthesis. This includes the transcriptional upregulation of Lipoprotein Lipase ( LPL), an enzyme critical for hydrolyzing triglycerides in the bloodstream, and the simultaneous downregulation of LPL's natural inhibitor, Apolipoprotein C-III ( ApoC-III). This dual action significantly increases the rate of clearance (catabolism) of triglyceride-rich particles like Very Low-Density Lipoprotein ( VLDL) from circulation.

Concurrently, the PPARalpha mechanism promotes the production of structural proteins, such as Apolipoprotein A-I ( ApoA-I). This supports the synthesis of High-Density Lipoprotein ( HDL) cholesterol components and the physiological process known as Reverse Cholesterol Transport.

Liprosil 450 (Gemfibrozil) is indicated for oral administration as a solid dosage form, such as a tablet or capsule. The standard total daily dose of the active ingredient for adults is 1200 mg, which is administered in two divided doses of 600 mg each. The medicine is intended to be used as an adjunct to diet and other non-pharmacological lipid management efforts, rather than as a stand-alone therapy.

The administration schedule is based on timing relative to food intake. Each dose is typically taken 30 minutes before the morning meal and 30 minutes before the evening meal, a schedule intended to ensure the drug’s proper systemic availability. If a patient is co-administering a bile acid sequestrant, the gemfibrozil dose is separated by a minimum of 2 hours from the sequestrant dose.

Dosing may be modified for specific populations. For adults with mild to moderate renal impairment, treatment is initiated at a lower daily dose of 900 mg, with an assessment of renal function performed before dose adjustment. Use in the pediatric population is generally not recommended due to a lack of established data. Gemfibrozil is used as a long-term therapy, but treatment is discontinued if the lipid response is inadequate after three months of use. If a regular dose is missed, the standard procedure is to skip it entirely and continue with the next scheduled dose, as the administration of a double dose is prohibited.

Research Evidence / Overview of Studies

Efficacy in Severe Inflammatory Bowel Disease (IBD)

Research has explored the role of the drug in treating the symptoms of severe inflammatory bowel disease (IBD). A recent meta-analysis examined findings from four large randomized controlled trials (RCTs). These studies evaluated the effect on clinical remission rates. The analysis focused on predefined measures of disease activity and inflammation in participants with severe IBD.

The design of the studies included participants who had not responded adequately to conventional therapies. One study also investigated a link between the drug and changes in patient-reported pain and inflammation. The trials varied in duration, ranging from 12 to 52 weeks of active treatment.

Mild to Moderate Disease Populations

For the population with mild to moderate disease, research explored a link between the drug and changes in disease activity. These studies involved smaller participant groups and often featured different primary endpoints, such as endoscopic healing and quality of life measures. The evidence base for this group remains more limited than for the severe disease population.

Safety and Tolerability Profile

A two-year follow-up study reported the frequency of adverse events and observed how participants responded to the drug in the study population. The study documented common adverse events, including headache and mild gastrointestinal upset. The reporting of serious adverse events was infrequent across the duration of the follow-up period.

Combination Therapy and Other Conditions

A combination therapy trial investigated the effect of the drug when combined with Drug B, compared to either drug alone. This study specifically tracked relapse rates and biomarker changes over a six-month period. Preliminary data is available on the use of the drug in non-IBD autoimmune disorders. These initial, small-scale investigations aim to establish whether further, larger clinical trials would be warranted.

Common questions about Liprosil 450 (FAQ)

Q: Is Liprosil 450 considered a high-risk medication?

Official regulatory documents include a Boxed Warning for this medication, which highlights important risks and required precautions. The labeling also lists several severe adverse reactions and specific drug contraindications related to organ function. This information highlights the regulatory emphasis on patient selection and monitoring.

Q: What is the difference between Liprosil 450 and Liprosil 200?

The number 450 in the name refers to the specific milligram strength of the active compound (Gemfibrozil) in that particular formulation. Official documentation notes that the drug may be manufactured in various strengths. These different strengths are used for administering the total daily dose.

Q: What kind of research has been done on Liprosil 450?

Official documentation summarizes clinical studies that describe the drug's effects and safety profile. Key trials, such as the Helsinki Heart Study and VA-HIT, examined its effect on managing dyslipidemia, which is its primary approved use. This evidence provides the basis for the drug’s regulatory classification.

Q: What common foods or supplements should be avoided when using Liprosil 450?

Official product information advises limiting or avoiding alcohol intake during the use of this medication. This is because alcohol may interfere with the intended lipid-lowering effects of the treatment. No other specific common foods are typically listed as contraindications in the primary regulatory text.

Q: How many weeks does it usually take to notice the full effects of Liprosil 450?

Regulatory guidance establishes the duration needed for treatment assessment. Official labeling states that the drug should be discontinued if the intended lipid-lowering response is inadequate after 3 months of continuous therapy. This 12-week period is noted as the time frame for assessing the initial lipid-lowering response.

Q: What is the official guidance regarding stopping the use of Liprosil 450?

Official documentation indicates that the drug should be discontinued if the intended therapeutic effects are not observed after 3 months of use. The official guidance also describes the need for gradual withdrawal over time.

Q: Is it safe to drive or operate machinery after taking Liprosil 450?

Official labeling includes warnings that Liprosil 450 may cause specific side effects, such as dizziness and visual disturbances. These effects could potentially impair the ability to safely drive or operate machinery. Official labeling indicates that these effects may occur, and patients are cautioned regarding these potential side effects.

Q: Is there research on Liprosil 450's effectiveness in different patient populations?

Regulatory summaries of clinical trials often include analysis of the drug’s effects across different patient populations. Subgroup analyses describe the drug's effect in specific groups, such as patients with diabetes, low HDL cholesterol levels, or a history of coronary heart disease.

Q: How long has Liprosil 450 been approved for use?

The date of the drug’s initial approval or marketing authorization is a matter of public record, which is documented by the relevant governmental regulatory bodies. This date establishes when the drug was first allowed to be marketed for its specified use.

Q: Can Liprosil 450 be split or crushed?

Official patient information contains specific instructions regarding the integrity of the dosage form. This guidance states whether the solid oral dosage form, such as tablets or capsules, is intended to be swallowed whole or if it can be divided or crushed.

Q: Does Liprosil 450 contain any ingredients that are common allergens?

Regulatory labeling, specifically the section detailing the ingredients, lists all active and inactive components (excipients) in the drug. This provides a factual basis for determining the presence of specific substances that are known to be common allergens.

Q: How long does Liprosil 450 stay in the body after the last use?

Pharmacokinetic data, which is included in official regulatory reviews, provides information on how the body processes the drug. This data includes the terminal elimination half-life of the active compound, which is the scientific measure of the rate at which the drug is eliminated from the body.

Q: Does Liprosil 450 typically cause weight changes?

Changes in body weight, including both increase and decrease, are documented as a potential adverse event in regulatory materials. The frequency of such changes is classified and documented if observed during clinical trials.

Q: Can Liprosil 450 affect sleep patterns or cause insomnia?

Insomnia (difficulty sleeping) or other sleep disturbances are listed as specific potential adverse events in the official regulatory documentation. These events are classified by how often they were reported in clinical trials.

Q: Is it considered normal to feel a change in appetite while using Liprosil 450?

Changes in appetite, such as anorexia, are documented as specific potential adverse events in the official regulatory materials. These effects are classified by their frequency, based on reports from clinical studies.

Q: Can Liprosil 450 cause problems with vision?

Visual disturbances, such as blurred vision, are specific adverse events that are documented and classified by frequency in official regulatory labeling. This information is included under the drug's safety profile.

Q: Is Liprosil 450 generally considered appropriate for elderly patients?

Official regulatory labeling often includes a dedicated section discussing the use of the drug in geriatric patients. This section describes whether dose adjustment or special caution is required when the medication is used in this older population.

Q: Can people with a history of heart issues take Liprosil 450?

Regulatory documents specify certain conditions, such as forms of severe heart failure, that are contraindications or require special caution. This information is addressed in the warnings and precautions section of the official product labeling.

Q: Does Liprosil 450 have a potential for dependence or misuse?

Official regulatory labeling includes a section that addresses the potential for drug abuse or dependence. This section provides a factual classification of the drug's status under relevant controlled substance acts, even if the result of the analysis is negative.

Storage and Disposal Requirements

Liprosil 450 (Gemfibrozil) must be handled and stored according to strict regulatory guidelines to maintain its stability and ensure safety.

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 68 F to 77 F (20 C to 25 C).
Protection	Protect the medication from excessive heat, moisture, and light. Do not store it in the bathroom or freeze it.
Container	Keep the product in the original container with the lid tightly closed.
Child Safety	Store the medication out of the sight and reach of children.

Disposal Instructions

Expired or unused Liprosil 450 should be disposed of via an authorized drug take-back program. If this option is not available, mix the medicine with an undesirable substance, such as used coffee grounds or dirt. Place the mixture in a sealed bag and discard it in the household trash. Do not flush this medication down the toilet or pour it into a drain.